Crossmark

Genome-wide copy number alteration and VEGFA amplification of circulating cell-free DNA as a biomarker in advanced hepatocellular carcinoma patients treated with Sorafenib

Crossref DOI link: https://doi.org/10.1186/s12885-019-5483-x

Published Online: 2019-04-01

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Oh, Chung Ryul

Kong, Sun-Young

Im, Hyeon-Su

Kim, Hwa Jung

Kim, Min Kyeong

Yoon, Kyong-Ah

Cho, Eun-Hae

Jang, Ja-Hyun

Lee, Junnam

Kang, Jihoon

Park, Sook Ryun

Ryoo, Baek-Yeol
License Information

Text and Data Mining valid from 2019-04-01
More Information

Article History

Received: 20 November 2018

Accepted: 15 March 2019

First Online: 1 April 2019

Ethics approval and consent to participate

: This prospective biomarker study was conducted under approval from the Institutional Review Board (IRB) at Asan Medical Center, Korea. All patients provided written informed consent before study enrollment.

: Not applicable.

: EHC, JHJ, and JL are employees of Genome Research Center, Green Cross Genome. All remaining authors declare no actual or potential conflicts of interest.Not applicable.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Document is current

Any future updates will be listed below